Education Manufacturing Medical Provider Provider 
Physician's Weekly
JUNE 18, 2025
Cost-sharing and education may improve access to GLP-1 therapies for obesity, but systemic barriers remain, requiring broader policy and clinical reforms. Waldrop, MD , and colleagues identified barriers to obesity medications more broadly—and potential solutions. They published their insights in Nature Medicine.
FDA Law Blog
MAY 26, 2025
Specifically, these are procedures and drugs used in providing what HHS had, until recently, referred to as gender-affirming care. Department of Health & Human Services purporting to provide a comprehensive review of the evidence and best practices for promoting the health of children and adolescents with gender dysphoria.
Expert insights. Personalized for you.
52 
Let's personalize your content